Taken together, these data indicate that PGRMC1 may be a therapeutic target in GBM and that patients with high tumour expression of PGRMC1 might benefit from individualized therapeutic approaches with ferroptosis inducers. The gene discussed is PGRMC1; the disease is neoplasm.